Click on the highlighted text and dots or the menu to link directly to additional information about each of these topics.

Candidate Indication Mechanism of Action Programme Status Partner
Discovery Phase Preclinical Development Clinical Phase I Clinical Phase II
IFN-β (SNG001) Asthma Virus Defence
IFN-β (SNG001) COVID-19 Virus Defence
IFN-β (SNG001) COPD Virus Defence
LOXL2 inhibitors IPF, NASH, Kidney Fibrosis & Cardiac Fibrosis Anti-fibrotic